Meta Pixel

News and Announcements

Focus – Risks getting the wrong investor in capital raising

  • Published December 20, 2022 4:37AM UTC
  • Publisher Callum Melrose
  • Categories Capital Raising Tips

As an early stage startup, there are a number of risks you face when raising capital. One risk that I was discussing recently, is the risk of ending up with an investor who doesn’t align with your company’s vision.

This can happen for a number of reasons.

Maybe you didn’t do your due diligence and didn’t understand the investor’s background or goals. Maybe you didn’t negotiate hard enough. Or maybe the investor is simply not a good fit for your company.

If an investor doesn’t align with your company, it can cause tension between the two parties, which could ultimately lead to a breakup of the investment. In worst case scenario, the investor could sabotage your company by forcing you to make changes that go against your core values.

So make sure you do your due diligence when searching for investors and always be prepared to walk away if the investment doesn’t feel right. And don’t forget to negotiate hard – a good investor will want a fair return on their investment, without causing damage to the business and you don’t want to give away too much without getting something in return.

If you have any other tips for avoiding common capital raising risks, please let me know in the comments! I would love to hear from you.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now